Clinical trial NCT00420888 - References

Renal Cell Carcinoma — ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

Citation(s)

•   Elkord E, Burt DJ, Sundstedt A, Nordle Ö, Hedlund G, Hawkins RE
  Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-a versus IFN-a. Oncotar
•   Hawkins RE, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P, Karyakin O, Khasanov R, Hedlund G, Forsberg G, Nordle O, Eisen T
  A Randomized Phase 2/3 Study of Naptumomab Estafenatox + IFN-a vs IFN-a in Renal Ce

A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma.

Details for clinical trial NCT00420888